In recent years, the demand for pigs as experimental animals for medical research has been increasing. Demand for model pigs that reproduce human diseases is also increasing, and development using genetic recombination and genome editing technologies is in progress. In addition, there is a huge demand for miniature pigs to save space and cost. NARO has jointly developed model pigs with hyperlipidemia, hemophilia, and immunodeficiency, and these are used to study diagnostic and therapeutic methods. Furthermore, we are promoting the miniaturization of immunodeficiency pigs with a perspective of using them in regenerative medical research, and we aim to promote their utilization in the medical research field.
We are working to improve the efficiency of model pig development by utilizing genome editing technology, which shows remarkable progress. Simultaneously, we are developing new control, preservation, and utilization technologies for germ cells and early embryos to establish systems that allows us to use biomaterials for genome editing at any time.
We have also established a method to produce immortalized cell lines from macrophages, a type of innate immune cells, in pigs. By utilizing this system as a model system, the functional analysis of various pathogens in pigs and the development of vaccines are expected to progress. We are also exploring the relationship between genetic diversity and resistance to infectious diseases and are aiming to develop strains of pigs with excellent disease resistance.
- UENISHI Hirohide (Leader)
- KIKUCHI Kazuhiro (Deputy Leader)
- FUCHIMOTO Daiichiro (Deputy Leader)
- HARAGUCHI Seiki
- SEMBON Shoichiro
- SUZUKI Syunichi
- NAKAI Michiko
- Tamas Somfai
- Thanh Quang Dang-Nguyen
- TAKENOUCHI Takato
- SUTO Jun'ichi
- OGAWA Tomoko